NICE guidance provides clear recommendations for GLP-1 use, which focus exclusively on glycaemic control in type 2 diabetes (NG28) and weight management in obesity (TA875 for semaglutide, TA664 for liraglutide)
This is because in the first three months of weight loss with GLP-1, supportive measures such as resistance training and sufficient protein intake can mitigate some of the sagging, hollowing and wrinkling and skin quality changes
Mechanistic investigations highlight that GLP-1 RAs have not just weight loss, but also anti-inflammatory and metabolic properties, suggesting their efficacy against several chronic conditions
Visit the location page of our website to find the location nearest you.
Since then, shortages have ended, and the FDA says [archived link] the non-approved compounded versions can no longer be made and sold